David, a brand that designs tools to increase muscle and decrease fat, today closed a $75 million Series A funding round, and announced the acquisition of Epogee, the food technology firm behind EPG, a plant-based fat alternative that significantly reduces calories and fat without compromising taste or texture. HG Ventures was an investor in Epogee.
In September 2024, David launched and debuted its flagship product: a protein bar with 28 grams of protein, zero sugar, and just 150 calories—offering the highest protein-to-calorie ratio on the market. The brand has experienced explosive growth over its first eight months of commercial operations, expanding into over 3,000 retail locations across the United States, most recently entering Wegmans. The brand is on pace to surpass $100 million in revenue in its first year of operation.
“Our mission is simple: to remove unnecessary calories and sugar from the American diet and replace them with what the body actually needs, which is high-quality protein,” said Peter Rahal, Co-Founder and CEO. “We’re building tools that make it easier to eat well without compromise. The response to David has been overwhelming, and this funding allows us to scale faster and stay focused on our mission of providing solutions to support and improve people’s health and well-being.”
David will use the investment to scale manufacturing, accelerate product development, and expand inventory to meet surging demand across retail and e-commerce. The Epogee acquisition is part of this growth strategy.
“We are not here to make another snack. We are here to advance nutrition,” added Rahal. “Acquiring Epogee strengthens our ability to scale by securing a key ingredient that helps us reduce calories and fat without compromising taste. This is about gaining control over our supply chain to move faster, stay true to our mission, and deliver food that improves health.”
In August of 2024, David closed a $10 million seed funding round. Notable investors include Dr. Layne Norton, Ph.D., Dr. Andrew Huberman, Ph.D., and Dr. Peter Attia, M.D., who serves as the brand’s Chief Science Officer.
With the Epogee acquisition, HG Ventures will benefit from David’s success, as a shareholder.